JP2020507328A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020507328A5 JP2020507328A5 JP2019543761A JP2019543761A JP2020507328A5 JP 2020507328 A5 JP2020507328 A5 JP 2020507328A5 JP 2019543761 A JP2019543761 A JP 2019543761A JP 2019543761 A JP2019543761 A JP 2019543761A JP 2020507328 A5 JP2020507328 A5 JP 2020507328A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- sequence
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022196214A JP2023029988A (ja) | 2017-02-10 | 2022-12-08 | Ｂｃｍａ、ｎｋｇ２ｄ及びｃｄ１６と結合するタンパク質 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762457780P | 2017-02-10 | 2017-02-10 | |
| US62/457,780 | 2017-02-10 | ||
| PCT/US2018/017653 WO2018148566A1 (en) | 2017-02-10 | 2018-02-09 | Proteins binding bcma, nkg2d and cd16 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022196214A Division JP2023029988A (ja) | 2017-02-10 | 2022-12-08 | Ｂｃｍａ、ｎｋｇ２ｄ及びｃｄ１６と結合するタンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020507328A JP2020507328A (ja) | 2020-03-12 |
| JP2020507328A5 true JP2020507328A5 (enExample) | 2022-12-26 |
| JP7257323B2 JP7257323B2 (ja) | 2023-04-13 |
Family
ID=63107848
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019543761A Active JP7257323B2 (ja) | 2017-02-10 | 2018-02-09 | Ｂｃｍａ、ｎｋｇ２ｄ及びｃｄ１６と結合するタンパク質 |
| JP2022196214A Pending JP2023029988A (ja) | 2017-02-10 | 2022-12-08 | Ｂｃｍａ、ｎｋｇ２ｄ及びｃｄ１６と結合するタンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022196214A Pending JP2023029988A (ja) | 2017-02-10 | 2022-12-08 | Ｂｃｍａ、ｎｋｇ２ｄ及びｃｄ１６と結合するタンパク質 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20190375838A1 (enExample) |
| EP (1) | EP3579876A4 (enExample) |
| JP (2) | JP7257323B2 (enExample) |
| KR (2) | KR20240078657A (enExample) |
| CN (1) | CN110461361A (enExample) |
| AU (1) | AU2018219348A1 (enExample) |
| BR (1) | BR112019016424A2 (enExample) |
| CA (1) | CA3054642A1 (enExample) |
| IL (1) | IL268567A (enExample) |
| MA (1) | MA47465A (enExample) |
| MX (1) | MX2019009566A (enExample) |
| MY (1) | MY205850A (enExample) |
| SG (1) | SG11201907253VA (enExample) |
| WO (1) | WO2018148566A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3131927B8 (en) * | 2014-04-14 | 2020-12-23 | Cellectis | Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy |
| CN110944651A (zh) | 2017-02-08 | 2020-03-31 | 蜻蜓疗法股份有限公司 | 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途 |
| AU2018219348A1 (en) * | 2017-02-10 | 2019-08-29 | Dragonfly Therapeutics, Inc. | Proteins binding BCMA, NKG2D and CD16 |
| EP4273258A3 (en) | 2017-02-20 | 2024-01-17 | Dragonfly Therapeutics, Inc. | Proteins binding her2, nkg2d and cd16 |
| IL311488A (en) * | 2017-08-23 | 2024-05-01 | Dragonfly Therapeutics Inc | Proteins that bind D2NKG, 16CD, and tumor-associated antigen |
| MX2020008333A (es) | 2018-02-08 | 2020-09-21 | Dragonfly Therapeutics Inc | Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales. |
| CA3090244A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
| CN112119093A (zh) | 2018-02-20 | 2020-12-22 | 蜻蜓治疗公司 | 结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法 |
| EA202091977A1 (ru) * | 2018-05-28 | 2021-02-09 | Драгонфлай Терапьютикс, Инк. | Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| CA3108427A1 (en) | 2018-08-08 | 2020-02-13 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use |
| CN113164570B (zh) | 2018-08-08 | 2024-05-14 | 蜻蜓疗法股份有限公司 | 结合nkg2d、cd16和肿瘤相关抗原的蛋白质 |
| AU2020279979A1 (en) * | 2019-05-20 | 2021-11-25 | Les Laboratoires Servier | Mcl-1 inhibitor antibody-drug conjugates and methods of use |
| AU2021268340A1 (en) | 2020-05-06 | 2022-12-08 | Dragonfly Therapeutics, Inc. | Proteins binding NKG2D, CD16 and CLEC12A |
| EP4161966A1 (en) | 2020-06-05 | 2023-04-12 | Eisai R&D Management Co., Ltd. | Anti-bcma antibody-drug conjugates and methods of use |
| CN116063550A (zh) * | 2020-09-02 | 2023-05-05 | 南京北恒生物科技有限公司 | 靶向nk激活性受体的嵌合抗原受体 |
| EP4225792A1 (en) * | 2020-10-08 | 2023-08-16 | Affimed GmbH | Trispecific binders |
| EP4301774A4 (en) | 2021-03-03 | 2025-08-13 | Dragonfly Therapeutics Inc | METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN |
| EP4301402A1 (en) | 2021-03-03 | 2024-01-10 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Bispecific antibodies enhancing cell mediated immune responses |
| AU2022246607A1 (en) * | 2021-03-31 | 2023-11-16 | Janssen Biotech, Inc. | Materials and methods for immune effector cells redirection |
| WO2024020577A2 (en) * | 2022-07-22 | 2024-01-25 | Fred Hutchinson Cancer Center | Antibodies against sars-cov-2 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007002905A1 (en) * | 2005-06-29 | 2007-01-04 | University Of Miami | Antibody-immune cell ligand fusion protein for cancer therapy |
| CN105837690A (zh) * | 2006-06-12 | 2016-08-10 | 新兴产品开发西雅图有限公司 | 具有效应功能的单链多价结合蛋白 |
| EP3663318A1 (en) * | 2008-01-07 | 2020-06-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| TW201109438A (en) | 2009-07-29 | 2011-03-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| EP2306234A3 (de) * | 2009-10-02 | 2011-06-22 | Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. | Optischer Aliasfilter, Pixelsensoranordnung und digitale Aufnahmevorrichtung |
| JP2014511836A (ja) * | 2011-03-25 | 2014-05-19 | グレンマーク ファーマシューティカルズ， エセ．アー． | ヘテロ二量体免疫グロブリン |
| TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| WO2013180200A1 (ja) * | 2012-05-30 | 2013-12-05 | 中外製薬株式会社 | 標的組織特異的抗原結合分子 |
| ES2597228T3 (es) | 2012-06-27 | 2017-01-17 | F. Hoffmann-La Roche Ag | Procedimiento para la selección y la producción de entidades de objetivación, como dianas, altamente selectivas y multiespecíficas, personalizadas, las cuales contienen por lo menos dos entidades de unión diferentes, y utilización de éstas |
| JP6636803B2 (ja) * | 2013-02-05 | 2020-01-29 | エンクマフ エスアーエールエル | Ｂｃｍａに対する抗体の選択のための方法 |
| HK1221908A1 (zh) * | 2013-04-29 | 2017-06-16 | Adimab, Llc | 多特异(polyspecificity)试剂，其制备方法和用途 |
| WO2015197582A1 (en) * | 2014-06-27 | 2015-12-30 | Innate Pharma | Monomeric multispecific antigen binding proteins |
| AU2015292744C1 (en) * | 2014-07-21 | 2021-01-21 | Novartis Ag | Treatment of cancer using humanized anti-BCMA chimeric antigen receptor |
| CN107530424A (zh) * | 2015-02-20 | 2018-01-02 | 俄亥俄州国家创新基金会 | 针对nkg2d和肿瘤相关抗原的二价抗体 |
| SG11201708257UA (en) * | 2015-04-06 | 2017-11-29 | Subdomain Llc | De novo binding domain containing polypeptides and uses thereof |
| US11291721B2 (en) * | 2016-03-21 | 2022-04-05 | Marengo Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
| US20200095327A1 (en) * | 2017-02-08 | 2020-03-26 | Dragonfly Therapeutics, Inc. | Antibody heavy chain variable domains targeting the nkg2d receptor |
| CN110944651A (zh) * | 2017-02-08 | 2020-03-31 | 蜻蜓疗法股份有限公司 | 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途 |
| AU2018219348A1 (en) * | 2017-02-10 | 2019-08-29 | Dragonfly Therapeutics, Inc. | Proteins binding BCMA, NKG2D and CD16 |
| EP3615068A1 (en) * | 2017-04-28 | 2020-03-04 | Novartis AG | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
-
2018
- 2018-02-09 AU AU2018219348A patent/AU2018219348A1/en not_active Abandoned
- 2018-02-09 KR KR1020247004861A patent/KR20240078657A/ko not_active Ceased
- 2018-02-09 JP JP2019543761A patent/JP7257323B2/ja active Active
- 2018-02-09 MX MX2019009566A patent/MX2019009566A/es unknown
- 2018-02-09 KR KR1020197026174A patent/KR20190115469A/ko not_active Ceased
- 2018-02-09 WO PCT/US2018/017653 patent/WO2018148566A1/en not_active Ceased
- 2018-02-09 CA CA3054642A patent/CA3054642A1/en active Pending
- 2018-02-09 EP EP18750616.7A patent/EP3579876A4/en active Pending
- 2018-02-09 US US16/484,936 patent/US20190375838A1/en active Pending
- 2018-02-09 BR BR112019016424-3A patent/BR112019016424A2/pt not_active Application Discontinuation
- 2018-02-09 MA MA047465A patent/MA47465A/fr unknown
- 2018-02-09 MY MYPI2019004552A patent/MY205850A/en unknown
- 2018-02-09 SG SG11201907253VA patent/SG11201907253VA/en unknown
- 2018-02-09 CN CN201880021558.4A patent/CN110461361A/zh active Pending
-
2019
- 2019-08-07 IL IL268567A patent/IL268567A/en unknown
-
2022
- 2022-12-08 JP JP2022196214A patent/JP2023029988A/ja active Pending